NEO celebrates listing

December 13 was a sweet day for NeoGenomics.

Company executives were at the Nasdaq headquarters to ring the closing bell and see NeoGenomics' name in lights on Times Square. The Fort Myers-based cancer-testing firm's stock started trading on Nasdaq earlier in the week with a new symbol, NEO.

The company's shares had been trading over-the-counter as NGNM. The shift to the Nasdaq will mean more visibility and liquidity for the company's stock, as a larger number of fund investors likely will consider buying the shares.

This is good news for NeoGenomics, which is growing its genetic cancer-testing operations in Fort Myers and elsewhere. The company reported a 26% jump in revenues in the most recent quarter to $14.2 million.

Besides its headquarters in Fort Myers, NeoGenomics has laboratories in Irvine, Calif., Nashville, Tenn., and Tampa. It provides cancer-test results to pathologists, oncologists, clinicians and hospitals around the U.S.